News
Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by 2025. Click here to read my SVRA analysis.
(RTTNews) - Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback